#1 Clinical Trials Search in Europe

Rilpivirine

Rilpivirine is an antiretroviral medication used in the treatment of HIV infection. This article explores various clinical trials investigating the use of rilpivirine in different patient populations and settings. The trials examine aspects such as safety, efficacy, pharmacokinetics, and comparisons to other HIV medications. Understanding these clinical trials provides valuable insights into how rilpivirine can be optimally used to manage HIV.

Table of Contents

What is Rilpivirine?

Rilpivirine is an antiretroviral medication used in the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. It is also known by its brand names Edurant, TMC278, and R278474[1][2]. Rilpivirine belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which work by blocking an enzyme that HIV needs to multiply[3].

How Rilpivirine Works

Rilpivirine works by inhibiting the action of an enzyme called reverse transcriptase. This enzyme is crucial for HIV to replicate and spread in the body. By blocking this enzyme, rilpivirine helps to reduce the amount of HIV in the blood (viral load) and increase the number of immune cells called CD4+ T cells, which are important for fighting infections[3][7].

Conditions Treated with Rilpivirine

Rilpivirine is primarily used to treat HIV-1 infection in adults and children. It is often prescribed for:

  • Treatment-naive patients (those who have never taken HIV medications before)[3]
  • Patients switching from other HIV medications, such as efavirenz or nevirapine[1][4]
  • Maintaining viral suppression in patients who have already achieved undetectable viral loads with other treatments[2]

Dosage and Administration

Rilpivirine is typically administered as follows:

  • For adults: The usual dose is 25 mg taken once daily with a meal[5]
  • For children and adolescents: The dosage may be adjusted based on age and weight. In some studies, a weight-adjusted dose or granules formulation has been used for younger children[7]
  • It is important to take rilpivirine with food to ensure proper absorption of the medication[5]

Efficacy and Safety

Clinical trials have shown that rilpivirine is effective in suppressing HIV viral load and improving CD4+ cell counts. Some key findings include:

  • Rilpivirine has demonstrated non-inferiority to efavirenz in maintaining viral suppression in some studies[1]
  • It has shown efficacy in both treatment-naive patients and those switching from other antiretroviral regimens[2][4]
  • Long-term safety studies have been conducted, with some following patients for up to 4 years or more[2]

Potential Side Effects

Like all medications, rilpivirine can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Dizziness
  • Fatigue
  • Skin rash[2]

More serious side effects, though less common, may include:

  • Changes in liver function
  • Depression or mood changes
  • Severe skin reactions[7]

It’s important to discuss any side effects with your healthcare provider.

Drug Interactions

Rilpivirine can interact with other medications. Some important interactions to note include:

  • Proton pump inhibitors (used for acid reflux) should not be taken with rilpivirine[5]
  • Certain medications that affect liver enzymes may alter the levels of rilpivirine in the body[6]
  • Switching from efavirenz to rilpivirine requires careful monitoring due to potential drug interactions[6]

Use in Special Populations

Research has been conducted on the use of rilpivirine in various populations:

  • Children and adolescents: Studies have evaluated the safety and efficacy of rilpivirine in children as young as 2 years old[7]
  • Pregnant women: Limited data is available on the use of rilpivirine during pregnancy. Discuss the risks and benefits with your healthcare provider if you are pregnant or planning to become pregnant[2]

Ongoing Research

Rilpivirine continues to be studied in various contexts:

  • Long-term safety and efficacy studies are ongoing[2]
  • Research is being conducted on its use in different formulations, such as long-acting injectable forms[7]
  • Studies are exploring its potential effects on cardiovascular health and other body systems[8]
Aspect Details
Drug Name Rilpivirine (also known as RPV, TMC278, Edurant)
Drug Class Non-nucleoside reverse transcriptase inhibitor (NNRTI)
Common Dosage 25 mg once daily with a meal
Populations Studied Adults, adolescents, children (including those under 12 years old)
Key Outcomes Measured Viral suppression, CD4 count changes, adverse events, pharmacokinetics
Trial Designs Open-label, randomized, single-arm, crossover studies
Comparator Drugs Efavirenz, other antiretroviral regimens
Safety Considerations Rash, changes in lipid profiles, neuropsychiatric effects
Special Populations Pediatric patients, treatment-naive patients, those switching from other regimens

FAQ

  • What is rilpivirine and how is it used? Rilpivirine is an antiretroviral medication used to treat HIV-1 infection. It belongs to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine is typically taken once daily with a meal as part of a combination antiretroviral therapy regimen.
  • What populations have been studied in rilpivirine clinical trials? Clinical trials have studied rilpivirine in various populations including treatment-naive adults, children and adolescents, and patients switching from other antiretroviral regimens. Some trials have focused specifically on pediatric populations under 12 years old.
  • How does rilpivirine compare to other HIV medications? Some trials have compared rilpivirine to other antiretroviral drugs like efavirenz. For example, one study looked at switching patients from efavirenz to rilpivirine and examined differences in side effects and efficacy. However, direct comparisons vary between trials.
  • What are some of the key safety and efficacy outcomes measured in rilpivirine trials? Common outcomes measured include viral load suppression, CD4 cell count changes, adverse events, drug resistance, and pharmacokinetic parameters. Some trials also looked at specific side effects like rash or changes in lipid profiles.
  • How long do typical rilpivirine clinical trials last? The duration of rilpivirine trials varies widely. Some pharmacokinetic studies may last only a few weeks, while long-term safety and efficacy trials can continue for several years. Many trials include 48-week primary outcome measures with extended follow-up periods.

Ongoing Clinical Trials on Rilpivirine

  • Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Germany Italy Portugal Spain

  • Study on HIV-1 Patients: Effects of Rilpivirine and Dolutegravir After Stopping Antiretroviral Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Long-Acting Cabotegravir and Rilpivirine for People Aged 60 and Over Living with HIV-1

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study of Rilpivirine for Children and Teens with HIV-1 from Previous Rilpivirine Studies

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on the Effectiveness and Safety of Lamivudine, Dolutegravir Sodium, Cabotegravir, and Rilpivirine for Adults with HIV-1 Who Have Not Taken Antiretroviral Therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Effectiveness of Rilpivirine-Based Treatment for HIV Patients with Metabolic Liver Disease Using Dolutegravir, Rilpivirine, and Emtricitabine/Tenofovir Combination

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Long-Acting Cabotegravir and Rilpivirine for HIV Patients in Spain: Evaluating Out-of-Hospital Treatment Options

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Spain

  • Study on the Effects of Abacavir Sulfate and Etravirine in Pregnant Women with HIV

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Ireland The Netherlands Spain

Glossary

  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time. This includes measuring drug concentrations in the blood and other tissues.
  • Virologic suppression: Reduction of HIV viral load in the blood to very low or undetectable levels, typically defined as less than 50 copies/mL, as a result of antiretroviral treatment.
  • CD4 cell count: A measure of the number of CD4 T lymphocytes (a type of white blood cell) in the blood. This is an important indicator of immune system health in people with HIV.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, whether or not considered related to the treatment.
  • Open-label trial: A type of clinical trial in which both the researchers and participants know which treatment is being administered.
  • Antiretroviral therapy (ART): The use of HIV medicines to treat HIV infection. It involves taking a combination of HIV medicines every day to suppress the virus and prevent disease progression.
  • Treatment-naive: Refers to patients who have never received treatment for a particular condition before, in this case, those who have never taken antiretroviral medications for HIV.
  • Viral load: The amount of HIV genetic material (RNA) in a blood sample, reported as number of HIV RNA copies per milliliter of blood.
  • Drug resistance: The ability of HIV to mutate and reproduce itself in the presence of antiretroviral drugs, potentially making the drugs less effective or ineffective.

References

  1. https://clinicaltrials.gov/study/NCT02104700
  2. https://clinicaltrials.gov/study/NCT02494986
  3. https://clinicaltrials.gov/study/NCT01562886
  4. https://clinicaltrials.gov/study/NCT03033368
  5. https://clinicaltrials.gov/study/NCT05358756
  6. https://clinicaltrials.gov/study/NCT01268839
  7. https://clinicaltrials.gov/study/NCT01975012
  8. https://clinicaltrials.gov/study/NCT01585038